Anti-TAT Binding Proteins for HIV Detection and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective anti-TAT antibodies that can detect and quantify TAT peptide, particularly for use in cellular delivery of heterologous cargo and therapeutic purposes in HIV infection treatment.
Innovation Solution
Development of anti-TAT binding proteins, including antibodies and antigen-binding portions, that specifically bind to the TAT protein transduction domain, which can be linked to various cargo moieties such as frataxin polypeptides or nucleic acids, enabling detection, quantification, and inhibition of TAT-mediated processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If anti-TAT antibodies are developed for detection and quantification, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent extracts and isolates the specific antigen-binding domains (CDR regions) from complete antibodies to create the core binding protein. By taking out only the essential antigen-binding portions (heavy chain CDR3 domain with SEQ ID NO: 4, and optionally light chain CDR3 domain with SEQ ID NO: 8 or 12), the invention achieves precise TAT peptide detection while reducing the complexity associated with developing and characterizing complete antibody structures.
Solution Approach 2:
The patent creates simplified copies of the essential antigen-binding functionality by using only the CDR domains rather than complete antibodies. These CDR-based binding proteins replicate the specific binding capability to TAT peptide sequences (such as YGRKKRRQRRR) without requiring the full antibody structure, thereby achieving measurement precision with reduced device complexity.
2Reliability
If anti-TAT antibodies are developed for therapeutic purposes, then reliability is improved, but device complexity increases
Solution Approach 1:
For therapeutic applications, the patent extracts the essential antigen-binding CDR domains and combines them with simplified constant regions or uses them as standalone binding proteins. This extraction approach maintains the reliable therapeutic effect of neutralizing TAT-mediated activities while reducing the complexity of constructing, producing, and administering complete antibody molecules.
Solution Approach 2:
The patent modifies the structural parameters of the antibody by using only the necessary CDR domains and minimal constant regions, changing the physical and chemical parameters such as molecular size, stability, and production requirements. This parameter change enables therapeutic application with improved reliability while managing construction complexity.
3Measurement precision
If binding proteins are designed to recognize specific TAT epitopes, then measurement precision is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent uses precisely defined CDR domain sequences (heavy chain CDR3: SEQ ID NO: 4; light chain CDR3: SEQ ID NO: 8 or 12) as simplified copies of the essential binding functionality. These standardized sequence copies ensure measurement precision through specific epitope recognition while providing clear manufacturing specifications that actually reduce precision requirements compared to developing complete novel antibodies.
Solution Approach 2:
The patent creates universal binding proteins based on conserved CDR sequences that can recognize multiple TAT peptide variants (wild-type and mutated). This universality achieves measurement precision across different TAT sequences while simplifying manufacturing, as the same CDR domain design can be used for various applications without requiring precise customization for each target variant.
Data Source
AI summary
The present invention encompasses TAT peptide binding proteins. Specifically, the invention relates to antibodies that specifically bind to a TAT protein transduction domain. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention for detection, quantification, purification and isolation of TAT protein transduction domain, e.g., a TAT fusion molecule comprising a TAT protein transduction domain, as well as methods of diagnosis and monitoring of HIV and AIDS are also provided herein.